Abstract
In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Current Drug Targets
Title: Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Volume: 8 Issue: 1
Author(s): Jochen Wiesner and Hassan Jomaa
Affiliation:
Keywords: Malaria, apicoplast, isoprenoid biosynthesis, DOXP reductoisomerase, fosmidomycin, FR900098
Abstract: In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-independent 1-deoxy-D-xylulose 5- phosphate (DOXP) pathway. The enzymes of the DOXP pathway are localised inside the plastid-like organelle (apicoplast). Fosmidomycin inhibits DOXP reductoisomerase, the second enzyme of this pathway. The antimalarial activity of fosmidomycin was established in vitro and in a rodent malaria model. Fosmidomycin alone or in combination with clindamycin was evaluated for the treatment of acute uncomplicated P. falciparum malaria in early phase II studies. Fosmidomycin monotherapy led to a fast parasite and fever clearance but was inefficient in radical elimination of the parasites. With the fosmidomycin-clindamycin combinations the cure ratio on day 28 was 100 % (10/10) with treatment durations of 5 and 4 days. The cure ratio was 90 % (9/10) with treatment duration of 3 days.
Export Options
About this article
Cite this article as:
Wiesner Jochen and Jomaa Hassan, Isoprenoid Biosynthesis of the Apicoplast as Drug Target, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315551
DOI https://dx.doi.org/10.2174/138945007779315551 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combinatorial Approaches to Iminosugars as Glycosidase and Glycosyltransferase Inhibitors
Combinatorial Chemistry & High Throughput Screening Peroxiredons: Tryparedoxin Peroxidase from Leishmania major
Current Regenerative Medicine (Discontinued) Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Terpenoids form the Sea: Chemical Diversity and Bioactivity
Current Organic Chemistry Advancement in Microbial Cheminformatics
Current Topics in Medicinal Chemistry Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding
Infectious Disorders - Drug Targets DNA Vaccines.
Current Molecular Medicine Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Reviews on Recent Clinical Trials Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-II
Current Topics in Medicinal Chemistry The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Pyrazoles and Fused Pyrimidines: Synthesis, Structure Elucidation, Antitubercular Activity and Molecular Docking Study
Medicinal Chemistry HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions
Current Immunology Reviews (Discontinued) Data Mining of Docking Results. Application to 3-Dehydroquinate Dehydratase
Current Bioinformatics Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Current Drug Targets Tuberculosis Detection from Chest Radiographs: A Comprehensive Survey on Computer-Aided Diagnosis Techniques
Current Medical Imaging Multivariate Calibration: A Powerful Tool in Pharmaceutical Analysis
Current Pharmaceutical Analysis